Theratechnologies (NASDAQ:THTX) Trading Down 0.8%

Shares of Theratechnologies Inc. (NASDAQ:THTX) were down 0.8% during trading on Friday . The company traded as low as $1.20 and last traded at $1.23. Approximately 15,228 shares changed hands during trading, a decline of 67% from the average daily volume of 45,984 shares. The stock had previously closed at $1.24.

Theratechnologies Price Performance

The firm has a 50-day moving average price of $1.39 and a two-hundred day moving average price of $1.36.

Theratechnologies (NASDAQ:THTX) last released its earnings results on Wednesday, July 10th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.04. The company had revenue of $22.02 million for the quarter. During the same period in the prior year, the firm posted ($0.40) EPS. On average, sell-side analysts anticipate that Theratechnologies Inc. will post -0.02 EPS for the current fiscal year.

Institutional Investors Weigh In On Theratechnologies

A number of institutional investors have recently added to or reduced their stakes in THTX. AIGH Capital Management LLC lifted its position in shares of Theratechnologies by 362.9% in the 4th quarter. AIGH Capital Management LLC now owns 3,719,302 shares of the company’s stock worth $6,025,000 after acquiring an additional 2,915,906 shares during the period. Worth Venture Partners LLC boosted its stake in Theratechnologies by 362.5% during the fourth quarter. Worth Venture Partners LLC now owns 906,557 shares of the company’s stock worth $1,469,000 after buying an additional 710,551 shares in the last quarter. National Bank of Canada FI increased its holdings in Theratechnologies by 65.4% in the 4th quarter. National Bank of Canada FI now owns 113,378 shares of the company’s stock valued at $191,000 after buying an additional 44,825 shares during the period. Finally, Wealthspire Advisors LLC acquired a new position in shares of Theratechnologies in the 4th quarter valued at $83,000.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.